An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

Also called NCT01574326

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 101 participants (enrolled count) (from the registry)
Sponsor
Genzyme, a Sanofi Company (from the registry)
Registry
  • NCT NCT01574326
  • EudraCT 2011-002329-23
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, France, Germany, Lithuania, Poland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01574326. Randomized; double masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2015-06 (actual). Results posted on 2016-07-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
Condition
Hyperphosphatemia
Intervention (Drug)
Placebo
Intervention (Drug)
Sevelamer carbonate
Lead sponsor
Genzyme, a Sanofi Company (class: industry)

Record details

Record id
cardio:ct-nct01574326
Content hash
f3be5b41ed75f72160f6f18e3b03a363cc49acfdcb47522b6ca16592a5850485